Medtronic to Acquire Intersect ENT for $1.1 Billion

Medtronic to Acquire Scientia Vascular

March 10, 2026

Medical Devices

Medtronic entered into a definitive agreement to acquire Scientia Vascular in a $550 million deal, with customary adjustments and potential earn-out/milestone payments. The acquisition combines Scientia’s neurovascular access devices (guidewires and catheters) with Medtronic’s existing neurovascular therapeutic portfolio to support faster and more reliable treatment for complex stroke cases.

Medtronic Acquires Nano Surface Technology Assets from Nanovis

February 12, 2025

Medical Devices

Medtronic plc acquired certain nano surface technology assets and related IP rights from Columbia City, Indiana-based Nanovis to support development of next-generation PEEK interbody fusion devices. Financial terms were not disclosed; the deal transfers Nanovis’ bone-growth nanotechnology (including rights related to Sites Medical’s OsteoSync titanium pads) to Medtronic for integration into its spinal implant portfolio.

Henry Schein Acquires Majority Interest in TriMed, Inc.

April 4, 2024

Medical Devices

Henry Schein, Inc. completed the acquisition of a majority interest in TriMed, Inc., a Santa Clarita, California–based developer of orthopedic implants and solutions for lower and upper extremities. TriMed reported approximately $52 million in 2023 net sales; the TriMed founders will remain with the business and financial terms were not disclosed. Henry Schein said the deal will broaden its surgical product offering to IDNs and ASCs and is expected to be neutral to 2024 non-GAAP EPS and accretive thereafter.

Integra LifeSciences Acquires Acclarent, Inc.

April 1, 2024

Medical Devices

Integra LifeSciences Holdings Corporation has completed its acquisition of Acclarent, Inc., a maker of ear, nose and throat (ENT) surgical devices. The transaction expands Integra’s product portfolio into the ENT device segment, adding approximately $1 billion to the company’s total addressable market and providing scale through Acclarent’s commercial and R&D capabilities.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.

Bioventus Inc. Acquires Misonix, Inc.

July 29, 2021

Medical Devices

Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. in a cash-and-stock transaction that values Misonix at approximately $518 million on a fully diluted basis. The deal expands Bioventus' regenerative medicine and surgical solutions portfolio by adding Misonix's minimally invasive ultrasonic technologies and regenerative wound products and is expected to close in the fourth quarter of 2021 subject to customary approvals.